NHMRC Clinical Trials Centre: FIELD study

NHMRC Clinical Trials Centre

Cardiovascular trials

FIELD

LIPID

VIGOUR

For information about the FIELD trial, and its results, go to
theFIELDtrial.org

Trials > Cardiovascular trials > FIELD

FIELD

FIELD chairman: Anthony Keech

The FIELD trial-Fenofibrate Intervention and Event Lowering in Diabetes-aimed to determine whether treatment with fenofibrate, a potent modifier of blood lipid levels, would reduce the risk of fatal coronary heart disease in people with type 2 diabetes.

FIELD was a double-blind placebo-controlled trial of prevention of coronary heart disease in people with type 2 diabetes. The trial was conducted in Australia, New Zealand and Finland.The trial began recruiting patients in early 1998, and randomly assigned the last of its 9795 participants in November 2000. Its five-year follow-up was completed during 2005. The results were reported in The Lancet in November 2005, and substudy analysis is continuing.

Main eligibility criteria:

type 2 diabetes mellitus with onset after the age of 35 years
men and women aged 50-75 years of age
average total cholesterol 3.0-6.5 mmol/L
triglycerides/high-density cholesterol ratio of 4.0 or higher, or triglycerides over 1.0 mmol/L

Type 2 diabetes and average total cholesterol

Fenofibrate for 5-7 years	Matching placebo
MORTALITY, CORONARY HEART DISEASE EVENTS, LIPID LEVELS

FIELD was internationally managed by the CTC. The international Management Committee has representatives from the three participating countries-Australia, New Zealand and Finland—and the sponsor, the French pharmaceutical company, Fournier Pharma.